Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder
eJHaem · 2026-12 · 7 (6)
DOI: 10.1002/jha2.70437 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 28.10.2026. Verfasst von Maria Mappoura und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Department of Oncology Geneva University Hospitals Geneva Switzerland. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Relapsed/refractory post‐transplant lymphoproliferative disorder (PTLD) remains a challenging complication after solid organ transplantation (SOT), requiring complex balancing of immune‐suppressive therapy (IST) and lymphoma‐directed therapies.
Methods
We report the case of a 40‐year‐old female kidney‐pancreas transplant recipient with relapsing monomorphic PTLD treated with CD19‐chimeric antigen receptor (CAR) T cells therapy (axicabtagene ciloleucel).
Results
Tacrolimus discontinuation and immunosuppression with everolimus and corticosteroids permitted robust CAR T‐cell expansion, complete lymphoma remission, and preservation of graft function. In vitro studies showed that tacrolimus inhibited CAR T‐cell function, while everolimus preserved it, supporting the use of mTOR‐based, calcineurin‐inhibitor‐free IST during CAR T‐cell therapy in SOT recipients. Conclusion mTOR‐based, calcineurin inhibitor–free immunosuppression can preserve CAR T‐cell function and enable effective therapy in SOT recipients with PTLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology Department of Oncology Geneva University Hospitals Geneva Switzerland.
- Translational Research Center For Oncohematology Department of Medicine Faculty of Medicine University of Geneva Geneva Switzerland.
- Department of Pathology and Immunology Faculty of Medicine University of Geneva Geneva Switzerland.
- Nephrology and Hypertension Division Department of Medicine Geneva University Hospitals Geneva Switzerland.
- Division of Clinical Pathology Geneva University Hospital Geneva Switzerland.
- Institute of Oncology Research Faculty of Biomedical Sciences Università Della Svizzera Italiana Bellinzona Switzerland.
Zitieren
APA
Mappoura, M., Hajj Younes, Y., Wang, S., Baldet, K., De Ramon Ortiz, C., Morin, S., Marouridi-Levrat, S., Pradier, A., Melotti, A., Purwar, P., Bernardi, C., Ho, L., Egervari, K., Ducreux, J., Longval, T., Bertoni, F., Chalandon, Y., Haidar, F., de Seigneux, S., …, & Simonetta, F. (2026). Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder. eJHaem, 7(6). https://doi.org/10.1002/jha2.70437
Vancouver
Mappoura M, Hajj Younes Y, Wang S, Baldet K, De Ramon Ortiz C, Morin S, et al. Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder. eJHaem. 2026;7(6). doi:10.1002/jha2.70437
BibTeX
@article{Mappoura2026,
author = {Mappoura, Maria and Hajj Younes, Yara and Wang, Sisi and Baldet, Kadiatou and De Ramon Ortiz, Carmen and Morin, Sarah and Marouridi-Levrat, Stavroula and Pradier, Amandine and Melotti, Astrid and Purwar, Pragallabh and Bernardi, Chiara and Ho, Liza and Egervari, Kristof and Ducreux, Julie and Longval, Thomas and Bertoni, Francesco and Chalandon, Yves and Haidar, Fadi and de Seigneux, Sophie and Villard, Jean and Olivier, Valérie and Simonetta, Federico},
title = {Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {6},
doi = {10.1002/jha2.70437}
}
EUVIMED